Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MDH1 | P40925 | 1/20 | 0.46 |
| ▸ | MDH2 | P40926 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31657216 | 0.91 | RAB9A (0.54) | SMN1; SMN2POLBNPC1RAB9ABLM | |
| SCHEMBL20029822 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBNPC1RAB9ABLM | |
| SCHEMBL31287068 | 0.87 | RAB9A (0.46) | SMN1; SMN2POLBNPC1RAB9ABLM | |
| SCHEMBL2832791 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBNPC1RAB9ABLM | |
| SCHEMBL322015 | 0.86 | ALDH1A1 (0.50) | SMN1; SMN2POLBNPC1RAB9ABLM | |
| SCHEMBL499346 | 0.86 | MAOB (0.55) | SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL1928759 | 0.86 | KMT2A (0.57) | POLBNPC1RAB9AMRGPRX4KMT2A | |
| SCHEMBL14002247 | 0.85 | ATM (0.46) | SMN1; SMN2POLBNPC1RAB9ABLM | |
| SCHEMBL15110547 | 0.85 | ALDH1A1 (0.55) | SMN1; SMN2POLBNPC1RAB9ABLM | |
| SCHEMBL17024452 | 0.85 | LMNA (0.53) | POLBKMT2AALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108472381-B | Compounds and therapeutic uses thereof | 森陶里治疗有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10112935-B2 | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| EP-1140913-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6271236-B1 | PHENYL UREAS/THIOUREAS AS INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE ENZYME, USEFUL IN TREATING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, AND VARICELLA-ZOSTER VIRUS | WYETH | 2001-08-07 | — | — | US | disclosed |
| US-6262090-B1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6262082-B1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | WYETH | 2001-07-17 | — | — | US | disclosed |
| US-6255349-B1 | PREVENTION REPRODUCTION; VIRICIDES | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| US-6207715-B1 | USEFUL IN THERAPY OF DISEASES ASSOCIATED WITH HERPES VIRUSES INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES-6 AND -7, AND KAPOSI HERPES VIRUS | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-27 | — | — | US | disclosed |
| US-6201013-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034269-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112935-B2 | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, CIT | SMN1; SMN2 4416/4885POLB 4870/4885NPC1 1326/4885 |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | SMN1; SMN2 3620/4885POLB 2382/4885NPC1 583/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | SMN1; SMN2 3620/4885POLB 2382/4885NPC1 583/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | SMN1; SMN2 3620/4885POLB 2382/4885NPC1 583/4885 |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, CIT | SMN1; SMN2 4416/4885POLB 4870/4885NPC1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.